Retrobulbar injection of triamcinolone in thyroid associated orbitopathy.

Objective: To identify the result of retrobulbar triamcinolone injection in patients with thyroid associated orbitopathy

Material And Method: Prospective noncomparative pilot study in 27 eyes of 19 patients who had been diagnosed as thyroid associated orbitopathy during October 2000 through April 2002. The patients received retrobulbar 40 mg triamcinolone treatment for each orbit weekly, totaling 4 applications.

Results: Three months after treatment, most of the patients demonstrated no significant change in visual acuity and visual field.